LIAN LianBio Stock Quote

LIAN [NASD]

Index	-	P/E	-	EPS (ttm)	-9.50	Insider Own	0.90%	Shs Outstand	107.28M	Perf Week	-11.11%
Market Cap	271.78M	Forward P/E	-	EPS next Y	-1.54	Insider Trans	0.00%	Shs Float	50.92M	Perf Month	-48.01%
Income	-	PEG	-	EPS next Q	-0.26	Inst Own	79.80%	Short Float	4.83%	Perf Quarter	-43.64%
Sales	-	P/S	-	EPS this Y	-40.60%	Inst Trans	-4.00%	Short Ratio	4.10	Perf Half Y	-84.18%
Book/sh	3.09	P/B	0.80	EPS next Y	-34.10%	ROA	-	Target Price	15.78	Perf Year	-
Cash/sh	3.37	P/C	0.74	EPS next 5Y	23.00%	ROE	-	52W Range	2.15 - 16.37	Perf YTD	-59.74%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-84.85%	Beta	-
Dividend %	-	Quick Ratio	15.40	Sales past 5Y	-	Gross Margin	-	52W Low	15.35%	ATR	0.42
Employees	107	Current Ratio	15.40	Sales Q/Q	-	Oper. Margin	-	RSI (14)	36.92	Volatility	9.84% 13.78%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	-113.60%	Profit Margin	-	Rel Volume	0.27	Prev Close	2.49
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	598.94K	Price	2.48
Recom	1.70	SMA20	-17.97%	SMA50	-33.00%	SMA200	-60.66%	Volume	159,276	Change	-0.40%

May-12-22 08:00AM	LianBio Reports First Quarter 2022 Financial Results and Provides Corporate Update GlobeNewswire +7.44%
May-09-22 08:00AM	LianBio Completes Phase 1 Pharmacokinetic Study of Mavacamten in Healthy Chinese Volunteers GlobeNewswire -8.94%
07:41AM	Is LianBio (NASDAQ:LIAN) In A Good Position To Invest In Growth? Simply Wall St.
May-05-22 04:05PM	LianBio to Participate in the Bank of America Securities 2022 Healthcare Conference GlobeNewswire -10.93%
May-03-22 08:00AM	LianBio Partner Tarsus Pharmaceuticals Announces Positive Topline Data from Second Pivotal Trial of TP-03 for the Treatment of Demodex Blepharitis GlobeNewswire -15.09%
Apr-29-22 08:15AM	U.S. Food and Drug Administration Approves Camzyos (mavacamten) for the Treatment of Adults with Symptomatic New York Heart Association Class II-III Obstructive Hypertrophic Cardiomyopathy (HCM) to Improve Functional Capacity and Symptoms GlobeNewswire -23.71%
Apr-14-22 04:10PM	LianBio Announces Formation of Scientific Advisory Board GlobeNewswire
Apr-07-22 07:08PM	LianBios Partner ReViral Enters into Acquisition Agreement with Pfizer GlobeNewswire +9.09%
08:00AM	LianBio Appoints Wei Wei Chen to Board of Directors GlobeNewswire
Mar-30-22 04:39PM	LianBio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update GlobeNewswire
Mar-10-22 06:12PM	LianBio Issues Statement Regarding the HFCAA GlobeNewswire -10.14%
Feb-15-22 07:00AM	LianBio Announces Mavacamten Granted Breakthrough Therapy Designation in China GlobeNewswire +18.52%
Feb-01-22 07:57AM	What Kind Of Investors Own Most Of LianBio (NASDAQ:LIAN)? Simply Wall St. +6.15%
Jan-10-22 07:00AM	LianBio Announces First Patient Dosed in Registrational Phase 3 EXPLORER-CN Trial of Mavacamten in Chinese Patients with Obstructive Hypertrophic Cardiomyopathy GlobeNewswire
Dec-21-21 07:00AM	LianBio Announces Infigratinib Approved Under Special Named Patient Program for the Treatment of Cholangiocarcinoma in the Pilot Zone of Hainan Province in China GlobeNewswire
Dec-09-21 04:30PM	LianBio Provides Corporate Update and Reports Third Quarter 2021 Financial Results GlobeNewswire
Dec-05-21 11:01AM	2 Stocks Raymond James Says Are Ready to Surge 60% or Higher TipRanks
Nov-01-21 02:26PM	LianBio Stock Stumbles in Trading Debut, Falls Below IPO Price Barrons.com
12:18PM	LianBio stock opens below the IPO price, reversing early indications of a rally MarketWatch
07:38AM	LianBio to go public as IPO prices in middle of expected range, as the biotech was valued at about $1.7 billion MarketWatch
Oct-31-21 08:21PM	LianBio Announces Pricing of Initial Public Offering GlobeNewswire

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor for ulcerative colitis and Crohn's disease; NX-13 for ulcerative colitis; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03, an eye solution for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Yu Debra	See Remarks	May 04	Option Exercise	1.71	1,000,000	1,710,000	1,000,000	May 06 04:15 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience